{"entity":{"id":"nct06055959","kind":"trial","name":"A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis","aka":[],"tldr":"A phase 2/3 trial of Zilucoplan in childhood cancers, run by UCB Biopharma SRL, now recruiting.","summary":"A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis is a phase 2/3 interventional study registered as NCT06055959 by UCB Biopharma SRL, with 8 participants planned, started 2024-10-16 and due to reach its primary completion in 2026-11-16. Interventions recorded: Zilucoplan.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06055959","url":"https://clinicaltrials.gov/study/NCT06055959"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["childhood-cancers"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["ucb"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06055959","phase":"2/3","setting":"A Multicenter Open-Label, Uncontrolled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Activity of Zilucoplan in Pediatric Study Participants From 2 to Less Than 18 Years of Age With Acetylcholine Receptor Antibody Positive Generalized Myasthenia Gravis","sponsor":"UCB Biopharma SRL","enrolled":8,"outcomes":[]},"route":"/trials/nct06055959/","neighbours":{"cancer":[{"id":"childhood-cancers","kind":"cancer","name":"Childhood cancers (all types)","route":"/cancers/childhood-cancers/"}],"company":[{"id":"ucb","kind":"company","name":"UCB","route":"/companies/ucb/"}]}}